Učitavanje...

4CPS-160 Use of apremilast in plaque psoriasis as an alternative to biologic treatments

BACKGROUND: Apremilast is a phosphodiesterase4 inhibitor. Two pivotal trials were carried out comparing apremilast to placebo in plaque psoriasis (PP). At week 16, significantly more patients taking apremilast achieved PASI75 (28.8%–33.1%) in both trials, versus placebo (5.3%–5.8%). PURPOSE: To asse...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Hosp Pharm
Glavni autori: Ruiz, M Pedrosa, Martinez, C Estaun, Moya-Carmona, I
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535597/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.251
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!